Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine… Read more
Collegium Pharmaceutical Inc (COLL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.285x
Based on the latest financial reports, Collegium Pharmaceutical Inc (COLL) has a cash flow conversion efficiency ratio of 0.285x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($78.44 Million) by net assets ($274.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Collegium Pharmaceutical Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Collegium Pharmaceutical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Collegium Pharmaceutical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Collegium Pharmaceutical Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Brigade Enterprises Limited
NSE:BRIGADE
|
-0.026x |
|
Nordic American Tankers Limited
NYSE:NAT
|
0.008x |
|
Vipshop Holdings Limited
NYSE:VIPS
|
N/A |
|
Netmarble Games Corp
KO:251270
|
0.027x |
|
PROG HOLDINGS A DL-50
F:AZD
|
N/A |
|
Piramal Pharma Limited
NSE:PPLPHARMA
|
0.046x |
|
Jiangsu Leili Motor Corp Ltd
SHE:300660
|
0.023x |
|
U.S. Physical Therapy Inc
F:UPH
|
0.025x |
Annual Cash Flow Conversion Efficiency for Collegium Pharmaceutical Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Collegium Pharmaceutical Inc from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $228.84 Million | $204.98 Million | 0.896x | -36.29% |
| 2023-12-31 | $195.43 Million | $274.75 Million | 1.406x | +120.50% |
| 2022-12-31 | $194.84 Million | $124.23 Million | 0.638x | +24.94% |
| 2021-12-31 | $202.93 Million | $103.56 Million | 0.510x | +1.06% |
| 2020-12-31 | $186.03 Million | $93.94 Million | 0.505x | +58.92% |
| 2019-12-31 | $87.43 Million | $27.78 Million | 0.318x | -82.82% |
| 2018-12-31 | $91.58 Million | $169.39 Million | 1.850x | +387.24% |
| 2017-12-31 | $104.08 Million | $-67.02 Million | -0.644x | -15.74% |
| 2016-12-31 | $134.91 Million | $-75.05 Million | -0.556x | -119.45% |
| 2015-12-31 | $85.07 Million | $-21.57 Million | -0.254x | -117.29% |
| 2014-12-31 | $-12.24 Million | $-17.95 Million | 1.466x | +149.51% |
| 2013-12-31 | $5.58 Million | $-16.53 Million | -2.961x | -- |